PTCT — PTC Therapeutics, Inc.
$63.49
+$0.13 (+0.21%)
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Market Cap
$5.30B
Forward P/E
19.9x
52-Week Range
N/A
PTCT Price History
Revenue vs. Net Income
$1.7B
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$411M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
44.0%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
0.9x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
17.3%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+14.9%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
